A recent trial on gantenerumab showed that the drug could reduce the risk of Alzheimer’s symptoms by 50% in pre-symptomatic ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains<a class="excerpt-read-more" href=" More ...

And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer's.

Initiative will eliminate up to 25% of all reauthorizations, or 10% of overall prior authorizations, PBM says.

Rather than seeking a single cure — a magic bullet — for Alzheimer’s disease, a shotgun blast of different drugs with different targets may be a better approach to this very complex condition.

Many trials exclude certain groups, and do so deliberately—children, for example, or people with physical or learning ...